Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPRAZOLAM vs SEIZALAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.
Generalized anxiety disorder,Panic disorder with or without agoraphobia,Anxiety (off-label),Insomnia (off-label),Chemotherapy-induced nausea and vomiting (off-label),Premenstrual dysphoric disorder (off-label)
Status epilepticus,Acute repetitive seizures,Seizure clusters
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Terminal elimination half-life is 15–20 hours in adults; prolonged in elderly and hepatic impairment (up to 40 hours).
Primarily hepatic via CYP3A4; major metabolites are alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive).
Hepatic via CYP3A4 and glucuronidation; active metabolite N-desmethylclobazam.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are excreted renally (approx. 70%) and fecal/biliary (approx. 30%).
80% (primarily to albumin, minor to α1-acid glycoprotein)
Approximately 98% bound to albumin.
0.8 L/kg (range 0.6-1.2 L/kg); clinical meaning: moderate tissue distribution, reflects lipophilicity; higher Vd in obesity
1.0–1.5 L/kg; reflects extensive tissue distribution.
Oral: 90% (immediate-release); extended-release: approximately 90% relative to immediate-release; sublingual: approximately 75-80% of oral
Oral: 70–90%; Intramuscular: 80–95% (relative to IV).
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 50% or consider alternative.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: reduce dose by 50%; hemodialysis: 0.25 mg daily
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Not FDA-approved for <18 years; limited data: 0.125 mg/kg/dose orally 3 times daily (max 0.02 mg/kg/dose) for panic disorder in adolescents.
0.01 mg/kg/dose (up to 0.5 mg) twice daily, titrate weekly to max 0.1 mg/kg/day (not to exceed adult max)
Start with 0.25 mg orally 2-3 times daily; increase slowly due to increased sensitivity and risk of falls; maximum 2 mg/day.
0.25 mg once daily initially; titrate slowly to 0.5 mg twice daily; max 2 mg/day
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Risk of respiratory depression, hypotension, and cardiac arrest; coadministration with CNS depressants increases risk.
Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; respiratory depression; worsening of depression or suicidal ideation; use in patients with acute narrow-angle glaucoma; impaired motor and cognitive performance; risk of severe allergic reactions.
Respiratory depression, hypotension, sedation, tolerance, withdrawal seizures, abuse potential, paradoxical reactions.
Concurrent use with ketoconazole or itraconazole; hypersensitivity to benzodiazepines; acute narrow-angle glaucoma; severe hepatic impairment; pregnancy (especially first trimester) and breastfeeding.
Hypersensitivity to benzodiazepines, severe respiratory insufficiency, myasthenia gravis, narrow-angle glaucoma.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing alprazolam levels and risk of toxicity. Avoid alcohol. No other significant food interactions.
Grapefruit and grapefruit juice may increase midazolam levels; avoid concurrent use. High-fat meals may reduce absorption of oral formulation; administer on empty stomach if possible.
First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties) with chronic high-dose use. Late third trimester: Risk of neonatal withdrawal syndrome.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restriction, preterm birth, neurodevelopmental deficits. Chronic use: Neonatal withdrawal syndrome, floppy infant syndrome.
Excreted into breast milk; M/P ratio approximately 0.3-0.5. Relative infant dose ~2-3% of maternal weight-adjusted dose. Clinical significance: low but may cause sedation, poor feeding, or withdrawal in neonates. Use caution, monitor infant for lethargy and weight gain.
M/P ratio 0.8; excreted into breast milk; levels low (0.1-0.5 mg/L). Monitor infant for sedation, poor feeding, weight loss. Caution recommended; alternative therapy if infant shows adverse effects.
Increased clearance and volume of distribution in pregnancy may require dose up-titration. Monitor clinical response; consider increasing dose by 20-50% in second and third trimesters. Avoid abrupt discontinuation; taper if needed. Use lowest effective dose for shortest duration.
Increased clearance and volume of distribution in pregnancy; dose increase of 30-50% often required to maintain therapeutic levels. Monitor trough concentrations and adjust as needed, especially in third trimester.
Alprazolam is a short-acting benzodiazepine with a rapid onset. Due to its high potency and short half-life, it carries a high risk of dependence and withdrawal. Avoid in patients with narrow-angle glaucoma, severe respiratory insufficiency, or myasthenia gravis. Use with caution in patients with history of substance abuse. Taper gradually to prevent rebound anxiety and seizures. Onset of action is 15-30 min orally; peak effect at 1-2 hours.
SEIZALAM (midazolam) is a short-acting benzodiazepine used for acute seizure control. Administer IV/IM; intranasal formulation available. Onset within 2-5 minutes. Monitor respiratory depression, especially with concurrent opioids. Flumazenil is reversal agent. Avoid in narrow-angle glaucoma. Dose adjust in elderly and hepatic impairment.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants as they can cause severe sedation and respiratory depression.,Do not drive or operate heavy machinery until you know how alprazolam affects you; it may cause drowsiness or dizziness.,Do not stop abruptly; withdrawal symptoms can include anxiety, insomnia, seizures, and life-threatening reactions.,Store at room temperature away from moisture and heat. Keep out of reach of children.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any worsening of depression or suicidal thoughts immediately.
Take exactly as prescribed; do not stop abruptly to avoid withdrawal seizures.,May cause drowsiness, dizziness; avoid driving or operating machinery.,Avoid alcohol and other CNS depressants.,Report any difficulty breathing, severe sedation, or rash immediately.,Store at room temperature away from light and moisture.
"Alprazolam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tetracaine, an ester-type local anesthetic. This additive or synergistic interaction can lead to excessive sedation, respiratory depression, and hypotension, particularly in elderly or debilitated patients. Concurrent use may also increase the risk of seizures due to tetracaine's proconvulsant activity at high doses, which is compounded by alprazolam's withdrawal-associated seizure risk."
"Co-administration of alprazolam, a benzodiazepine, with indinavir, a potent CYP3A4 inhibitor, significantly increases alprazolam's serum concentration and half-life via reduced hepatic metabolism, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Conversely, indinavir levels may be modestly increased due to competition for metabolism. This interaction poses a risk of severe central nervous system depression and should be avoided if possible."
"Concurrent use of alprazolam, a benzodiazepine with central nervous system depressant effects, and proparacaine, a topical ophthalmic anesthetic that can be systemically absorbed, may lead to additive CNS depression. This interaction can manifest as increased sedation, dizziness, confusion, or respiratory depression, especially in patients with compromised respiratory function or those receiving high doses of either agent. Clinicians should exercise caution when combining these drugs due to the potential for enhanced adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPRAZOLAM vs SEIZALAM, answered by our medical review team.
ALPRAZOLAM is a Benzodiazepine that works by Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.. SEIZALAM is a Benzodiazepine Anticonvulsant that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPRAZOLAM and SEIZALAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPRAZOLAM is: 0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.. The standard adult dose of SEIZALAM is: 0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPRAZOLAM and SEIZALAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPRAZOLAM is classified as Category D/X. First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome. SEIZALAM is classified as Category C. First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restrict. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.